Company intelligence / Profile preview

Jiangxi Shanliang Pharmaceutical

Jiangxi, China

Ownership: Private
Development stage: Other

Overview

Jiangxi Shanliang Pharmaceutical is currently engaged in a Phase 3 clinical trial for VVN001, an eye drop targeting dry eye disease as a LFA-1 antagonist, in partnership with VivaVision. The company is also advancing a joint venture for contact lens care products, but no large-scale, multi-indication drug development pipeline or platform technology is reported.[5][6]

Therapeutic areas: Ophthalmology
Modalities: Small moleculeDevice
Industry: Biotech

Partnerships

VivaVision

Beyond the preview

Go deeper on Jiangxi Shanliang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiangxi Shanliang Pharmaceutical.

Explore the full profile